Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
批准号:
10388193
负责人:
GENHONG CHENG
金额:
$75.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-05-02 至 2025-04-30
关键词:
AddressAffectAfricanAge-MonthsAmericanAmericasAnatomyAnti-Inflammatory AgentsAntibodiesAsianBiteBloodCD14 geneCell physiologyCellsClinicalCollaborationsComplexCulicidaeDNA Sequence AlterationDataDefectDevelopmentDiseaseDisease OutbreaksEpidemicEvolutionExposure toGeneticGenomicsGenotypeGeographyHumanImmuneImmune responseImmune systemImmunityImmunoglobulin MImmunologicsImmunosuppressionInfantInfectionInflammationJointsLeadLifeMaternal-Fetal TransmissionMeasuresMediatingMethodsMicrocephalyMolecularMothersMutationOutcomePathogenesisPathogenicityPatientsPatternPerinatalPeripheralPlacentaPoint MutationPopulationPregnancyPregnancy OutcomePregnant WomenProspective cohortPublishingRNA SequencesRecurrenceRelapseReportingResearch PersonnelRubellaSeverity of illnessSpecimenStructural Congenital AnomaliesSyndromeTestingThailandTimeUrineVertical Disease TransmissionViralViral GenomeViral Load resultViral PathogenesisViremiaVirusVirus SheddingZIKV infectionZika Virusadverse outcomeadverse pregnancy outcomeantenatalbasecohortcongenital infectioncytokinefetalfollow-upgenetic evolutiongenomic RNAin uteroin vivoinfant infectioninfant outcomemacrophagemonocytemouse modelneurodevelopmentneutralizing antibodypregnantprospectiveresponsetranslational studytransmission processvirus genetics
中文摘要
抽象/总结
英文摘要
Abstract/Summary
Our group of investigators has been collaborating over the last two years to describe the clinical aspects and
pathogenesis of in utero transmission of ZIKA virus (ZIKV) infection. We have embarked in a strong
collaborative effort to document and understand the pathogenesis of ZIKV. We have available to us a unique
prospective cohort of well characterized ZIKV-infected mother-infant pairs who have been followed since the
antenatal period, with infants now between 12 to 24 months of age and specimens collected over time. We
propose to characterize ZIKV humoral immune responses over time in our cohort of mother-infant pairs who
became infected during the Rio de Janeiro 2015/16 epidemic, in order to determine the timing of development
of immune responses to ZIKV in perinatally infected infants, and possible correlation with intermittent viral
shedding. We plan to evaluate whether infant immune responses are associated with the breadth and potency
of maternal immunologic responses to ZIKV over time. To do so we will measure neutralizing antibody activity
in 100 mother-infant pairs over 3 years and explore potential associations with annual infant
neurodevelopmental assessments and timing of infection in gestation. We will also investigate genetic viral
evolution in their ZIKV isolates and are presently sequencing whole ZIKV genome from mother-infant pairs
from the same cohort who had adverse pregnancy outcomes, normal pregnancy outcomes, recurrent or
relapsing infections, while also checking whether there is variability in viral sequences by compartment (CSF,
blood, urine, placenta). We are also evaluating specific ZIKV-immune responses at the cellular and molecular
levels and determining mechanisms by which the virus evades host immune responses during pregnancy. Our
findings will answer important questions pertaining to the mechanisms of immune pathogenesis and intrinsic
virologic factors associated with ZIKV mother-to-child transmission which may be predictive of longer term
infant outcomes. Our well characterized population of mother-infant pairs with detailed clinical follow-up and
specimens collected over time allows us to perform state of the art translational studies to elucidate
mechanisms of viral pathogenesis.
期刊论文(87)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1371/journal.pntd.0010133
发表时间:
2022-03
期刊:
PLoS neglected tropical diseases
影响因子:
3.8
作者:
[Rosser JI, Nielsen-Saines K, Saad E, Fuller T]
通讯作者:
Fuller T
Publisher Correction: SERPINB1-mediated checkpoint of inflammatory caspase activation.
出版商更正:SERPINB1 介导的炎症 caspase 激活检查点。
DOI:
10.1038/s41590-019-0361-x
发表时间:
2019
期刊:
Nature immunology
影响因子:
30.5
作者:
[Choi,YounJung, Kim,Stephanie, Choi,Younho, Nielsen,TravisB, Yan,Jun, Lu,Alvin, Ruan,Jianbin, Lee,Hye-Ra, Wu,Hao, Spellberg,Brad, Jung,JaeU]
通讯作者:
Jung,JaeU
Time to Evaluate the Clinical Repercussions of Zika Virus Vertical Transmission? A Systematic Review.
是时候评估寨卡病毒垂直传播的临床影响了吗?系统评价。
DOI:
10.3389/fpsyt.2021.699115
发表时间:
2021
期刊:
Frontiers in psychiatry
影响因子:
4.7
作者:
[do Amaral YNDV, Malacarne J, Brandão PG, Brasil P, Nielsen-Saines K, Moreira MEL]
通讯作者:
Moreira MEL
Mobile Solutions for Clinical Surveillance and Evaluation in Infancy-General Movement Apps.
用于婴儿期运动应用程序中临床监视和评估的移动解决方案。
DOI:
10.3390/jcm12103576
发表时间:
2023-05-20
期刊:
Journal of clinical medicine
影响因子:
3.9
作者:
[Marschik PB, Kwong AKL, Silva N, Olsen JE, Schulte-Rüther M, Bölte S, Örtqvist M, Eeles A, Poustka L, Einspieler C, Nielsen-Saines K, Zhang D, Spittle AJ]
通讯作者:
Spittle AJ
DOI:
10.3390/v14061173
发表时间:
2022-05-28
期刊:
Viruses
影响因子:
--
作者:
[]
通讯作者:
共 50 条
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10222540
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10174522
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
-
批准号:10461773
-
项目类别:
-
资助金额:$38.03万
-
财政年份:2020
-
负责人:GENHONG CHENG
-
依托单位:
Genetic evolution, pathogenesis and immune responses in mother to child transmission of ZIKV
-
批准号:9925059
-
项目类别:
-
资助金额:$75.04万
-
财政年份:2018
-
负责人:GENHONG CHENG
-
依托单位:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
-
批准号:8039043
-
项目类别:
-
资助金额:$22.54万
-
财政年份:2011
-
负责人:GENHONG CHENG
-
依托单位:
IKKa-Dependent Negative Feedback Control of Non-Canonical NF-kB Activation
-
批准号:8208992
-
项目类别:
-
资助金额:$18.69万
-
财政年份:2011
-
负责人:GENHONG CHENG
-
依托单位:
Mitiagrion of Radiation Damage by Mechanisms of Innate Immune Regulation
-
批准号:8011751
-
项目类别:
-
资助金额:$36.38万
-
财政年份:2010
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8091282
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8481502
-
项目类别:
-
资助金额:$34.54万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7741382
-
项目类别:
-
资助金额:$31.24万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:8282723
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7868050
-
项目类别:
-
资助金额:$37.12万
-
财政年份:2009
-
负责人:GENHONG CHENG
-
依托单位:
Role of IRF3 and RXRa Crosstalk in Host Response to Viral Infections
-
批准号:7687186
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7644341
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7388575
-
项目类别:
-
资助金额:$28.28万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:8067083
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Regulation of Type 2 NF-kappaB Activation and Inflammation
-
批准号:7810716
-
项目类别:
-
资助金额:$28.0万
-
财政年份:2008
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:7587981
-
项目类别:
-
资助金额:$32.37万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:8636981
-
项目类别:
-
资助金额:$37.84万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
Viral Mediated Type I Interferon Induction
-
批准号:9458084
-
项目类别:
-
资助金额:$68.78万
-
财政年份:2006
-
负责人:GENHONG CHENG
-
依托单位:
海外基金